![Karl Erik Hellström](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karl Erik Hellström
No más puestos en curso
Perfil
Dr. Hellström received his M.D.
and Ph.D.
degrees from Karolinska Institute in Stockholm, Sweden, initially working in the area of tumor biology with an emphasis on immunogenetics.
As a student of George Klein, he was a member of the team that showed, for the first time, a tumor-destructive immune response to an animal's own autologous tumor.
After being recruited to the faculty of the University of Washington Medical School in 1966, Karl Erik Hellström and his wife, Dr. Ingegerd Hellström became internationally known after they reported that there is a T-lymphocyte-mediated immune response to human tumors, a discovery that opened new avenues for research and development of cancer therapy.
Antiguos cargos conocidos de Karl Erik Hellström.
Empresas | Cargo | Fin |
---|---|---|
MARKER THERAPEUTICS, INC. | Director/Miembro de la Junta | 05/12/2005 |
SEAGEN INC. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MARKER THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Seagen Inc.
![]() Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Karl Erik Hellström